PRODUCT INFORMATION



Capadenoson

Item No. 28422

CAS Registry No.:	544417-40-5	
Formal Name:	2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl] methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]- 3,5-pyridinedicarbonitrile	NH ₂
Synonym:	BAY 68-4986	NC
MF:	$C_{25}H_{18}CIN_5O_2S_2$	
FW:	520.0	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 295, 346 nm	
Supplied as:	A solid	-
Storage:	-20°C	
Stability:	≥4 years	
Information represent	s the product specifications. Batch specific analytical re	sults are provided on each certificate of analysis

Laboratory Procedures

Capadenoson is supplied as a solid. A stock solution may be made by dissolving the capadenoson in the solvent of choice, which should be purged with an inert gas. Capadenoson is soluble in DMSO.

Description

Capadenoson is an orally bioavailable, non-nucleoside adenosine (A) receptor partial agonist.^{1,2} It binds selectively to human A_1 and A_{2B} (EC₅₀s = 0.66 and 1.1 nM, respectively) over A_{2A} and A_3 receptors (EC₅₀s = 1,413 and 240 nM, respectively) expressed in CHO cells.¹ Capadenoson (0.6 μ M) decreases electrical field-stimulated norepinephrine (Item No. 16673) release from isolated perfused hearts from spontaneously hypertensive rats (SHR) but not from control rats.³ It does not affect baseline heart rate but protects against stress-induced increases in heart rate in SHR but not control rats when administered at a dose of 0.15 mg/kg for 5 days prior to stress induction. Capadenoson (0.1 mg/kg) decreases cardiac infarct size from 28.7 to 22% in a mouse model of ischemia induced by left anterior descending artery (LAD) occlusion.² Capadenoson (7.5 mg twice per day) also increases the left ventricular ejection fraction (LVEF) in a dog model of microembolization-induced heart failure.⁴

References

- 1. Baltos, J.-A., Vecchio, E.A., Harris, M.A., et al. Capadenoson, a clinically trialed partial adenosine A receptor agonist, can stimulate adenosine A_{2B} receptor biased agonism. Biochem. Pharmacol. 135, 79-89 (2017).
- 2. Meibom, D., Albrecht-Küpper, B., Diedrichs, N., et al. Neladenoson bialanate hydrochloride: A prodrug of a partial adenosine A_1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 12(10), 728-737 (2017).
- Bott-Flugel, L., Bernshausen, A., Schneider, H., et al. Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. PLoS One 6(3), e18048 (2011).
- Sabbah, H.N., Gupta, R.C., Kohli, S., et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ. Heart Fail. 6(3), 563-561 (2013).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM